Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by MineDiggeron Dec 03, 2020 6:30am
205 Views
Post# 32024411

RE:RE:RE:Some Clarifications and Comments

RE:RE:RE:Some Clarifications and Comments

Thanks for the clarificationjd, but that throws an interesting light on your August post:


"I will not discuss it [Digitel] much further except to point out that I am not paid by Bioasis for IR work or for my posting here or anywhere else. With respect to expressing my opinions about Bioasis, I remain as independent from Bioasis as any other shareholder."

[My Highlights]

But, as usual, I look forward to your scientific insights, although given the above and the absent CEO insight I'm less convinced than I was.

MD
<< Previous
Bullboard Posts
Next >>